Patient Safety Authority Logo

Skip navigation links
HOME
PATIENT SAFETY AUTHORITYExpand PATIENT SAFETY AUTHORITY
PA-PSRS and PASSKEYExpand PA-PSRS and PASSKEY
PATIENT SAFETY ADVISORIESExpand PATIENT SAFETY ADVISORIES
PATIENTS AND CONSUMERSExpand PATIENTS AND CONSUMERS
NEWS AND INFORMATIONExpand NEWS AND INFORMATION
EDUCATIONAL TOOLSExpand EDUCATIONAL TOOLS
AUTHORITY EVENTSExpand AUTHORITY EVENTS







ADDRESS:

Patient Safety Authority
333 Market Street
Lobby Level
Harrisburg, PA 17120


Phone: 717-346-0469
Fax: 717-346-1090


 
Advisory Banner
Keeping an Eye on Toxic Anterior Segment Syndrome
PA PSRS Patient Saf Advis 2006 Dec;3(4):14. 
 

Editor’s Note: The following information has been abstracted from the cover article of the December 2006 AORN Journal. PA-PSRS Clinical Analyst Janet Johnston, RN, MSN, JD, was invited to submit the article for publication. Additional resources have been provided.

Since June 2004, ambulatory surgical facilities have submitted at least 15 reports of toxic anterior segment syndrome (TASS) to PA-PSRS, and at least three facilities have reported multiple cases. TASS is a complication of intraocular surgery that occurs when a non-infectious toxic agent enters the anterior segment of the eye and causes an inflammatory reaction. While it is a rare complication, severe cases of TASS can cause permanent injury to the eye. Often, the cause of a TASS event remains unknown even after investigation, but potential causes identified in the clinical literature include bacterial endotoxin, viscoelastic, and other residues introduced into the eye (e.g., on instruments); solutions and intraocular fluids introduced into the eye; preservatives in ophthalmic solutions; medications that penetrate through surgical wounds in the eye; and intraocular lenses (i.e., design and composition).

TASS incidence is difficult to pinpoint for several reasons, including that TASS is often confused with and treated as infectious endophthalmitis. Symptoms (e.g., decreased or blurred vision, hypopyon, fibrin and conjuctival redness) are similar for both diagnoses—a complete evaluation conducted by an ophthalmologist will differentiate between the two. Such an examination comprises the following: fundus examination, gonioscopy, slit lamp examination, tonometry, and aqueous and vitreous needle examination. If early diagnosis of TASS is made, timely and appropriate intervention is effective. Treatments vary, but the most common treatment is administering corticosteroids to reduce inflammation. After treatment, careful monitoring and follow-up protects against further inflammation.

Risk-reduction strategies for clinicians, surgical team members, patients, and others to consider include the following:

  • Awareness 
    • Acknowledging the potential for TASS to occur (e.g., quickly investigating and appropriately treating inflammation that occurs the day after surgery)
    • Being wary of all items introduced into the eye during surgery
    • During discharge, instructing patients to return at first indication of visual disturbance
  • Communication
    • Involving perioperative personnel in discussions about purchasing changes to avoid supply items associated with TASS
    • Discussing intraoperative changes that could contribute to TASS (e.g., intraoperative switch to different irrigating solution)
    • Documenting and recording medications, solutions, and instruments used in surgery to help identify patterns in the event of TASS outbreak
  • Technique
    • Considering techniques to reduce the risk of TASS discussed in clinical literature

Source: Johnston J. Toxic anterior segment syndrome— more than sterility meets the eye. AORN J 2006 Dec [cited 2006 Dec 6]. Available from Internet: http://www.aornjournal.org/article/PIIS000120920663994X/abstract.

Additional Resources

American Society of Cataract and Refractive Surgery

cme2 (an independent subsidiary of Advanstar Communications,Inc)

  • TASS: Probable Causes and Corrective Measures [Web site]. [cited 2006 Dec 8]. Available from Internet: http://www.tassfacts.com/.
 
 Browse by Topic
Navigation  



THE PENNSYLVANIA PATIENT SAFETY AUTHORITY AND ITS CONTRACTORS  
PSA LOGO The Pennsylvania Patient Safety Authority is an independent state agency created by Act 13 of 2002, the Medical Care Availability and Reduction of Error (“Mcare”) Act. Consistent with Act 13, ECRI Institute, as contractor for the Authority, is issuing this publication to advise medical facilities of immediate changes that can be instituted to reduce Serious Events and Incidents. For more information about the Pennsylvania Patient Safety Authority, see the Authority’s Web site at www.patientsafetyauthority.org .      
ECRI LOGO ECRI Institute, a nonprofit organization, dedicates itself to bringing the discipline of applied scientific research in healthcare to uncover the best approaches to improving patient care. As pioneers in this science for more than 40 years, ECRI Institute marries experience and independence with the objectivity of evidence-based research. More than 5,000 healthcare organizations worldwide rely on ECRI Institute’s expertise in patient safety improvement, risk and quality management, and healthcare processes, devices, procedures and drug technology.      

ISMP Logo The Institute for Safe Medication Practices (ISMP) is an independent, nonprofit organization dedicated solely to medication error prevention and safe medication use. ISMP provides recommendations for the safe use of medications to the healthcare community including healthcare professionals, government agencies, accrediting organizations, and consumers. ISMP’s efforts are built on a nonpunitive approach and systems-based solutions.      
 
©2012 Pennsylvania Patient Safety Authority                                                Home      Who We Are      Contact Us     Subscribe to Advisories and Press Releases   Site Map     Privacy Statement